Mail

CRON.TO - Cronos Group Inc.

Toronto - Toronto Delayed Price. Currency in CAD

20.67

+0.04 (+0.19%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	20.63
Open	20.90
Bid	20.61 x 0
Ask	20.67 x 0
Day's Range	20.61 - 21.55
52 Week Range	7.33 - 32.95
Volume	848,527
Avg. Volume	1,796,170

Market Cap	6.884B
Beta (3Y Monthly)	4.70
PE Ratio (TTM)	37.18
EPS (TTM)	0.56
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	14.55

All

News

Press Releases

The Motley Fool5 hours ago
Will the Cannabis Industry See Another Hot Summer?
Last year's red-hot summer left investors wanting more from stocks like Canopy Growth Corp (TSX:WEED)(NYSE:CGC), Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON), and Hexo Corp. (TSX:HEXO).
Motley Fool7 hours ago
Better Marijuana Stock: Cronos Group vs. Green Thumb Industries
Which stock wins in a matchup between a leading Canadian marijuana producer and a top U.S. cannabis operator?
The Motley Fool3 days ago
Bitcoin and Marijuana: Profiting From the Latest Market Bubble
Despite a growing valuation disconnect, Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) is poised to make further gains.
Market Realist3 days ago
Does Cronos Group Look Expensive at the Current Price?
Cronos Group: Analysts' Ratings and Target Price Update(Continued from Prior Part)Cronos GroupCronos Group (CRON) has been trading at a significant premium to the peer average in May—a continuation of the trend over the past several months. The
Market Realist3 days ago
Cronos Group: Analysts’ Ratings and Target Price
Cronos Group: Analysts' Ratings and Target Price UpdateCronos Group’s ratingsCronos Group (CRON) has experienced an increase in the number of analysts covering the stock. Six analysts covered the stock at the beginning of the year—compared to
Market Realist4 days ago
Cannabis Stocks Struggle to Find Direction
Why Canopy Growth Is on the Rise Today(Continued from Prior Part)Cannabis sectorThe cannabis sector has been struggling to find direction on May 22, with cannabis stocks trading on a largely mixed note in the first half. During the first half of the
Market Realist4 days ago
How Cronos Group and Aurora’s Valuations Compare with Peers
How Do Cannabis Stocks' Valuations Stack Up in May?(Continued from Prior Part)Cronos GroupCronos Group (CRON) saw a big spike in its forward EV-to-EBITDA valuation multiple compared to its historical average as shown in the chart below. The company
Market Realist4 days ago
Is Now a Good Time to Buy Cannabis Stocks?
How Do Cannabis Stocks' Valuations Stack Up in May?(Continued from Prior Part)Investing in the cannabis sectorThe cannabis sector has had its ups and downs in the past month. The trend has mostly been flat to downwards-trending for most of the
CNBC5 days ago
Cramer Remix: The cannabis stocks I'm eyeing
"The charts, as interpreted by Tim Collins, suggest that GW Pharma and Village Farms are buys here," Jim Cramer says. "I think you should stick with Canopy Growth, and Collins believes that GW Pharma is the best bet out there," he says. "The charts, as interpreted by Tim Collins, suggest that GW Pharma GW2-FF and Village Farms VFF-CA are buys here," the "Mad Money" host said.
The Motley Fool5 days ago
Is Cronos Group (TSX:CRON) a Buy Right Now?
There are things to admire about Cronos Group (TSX:CRON) (NASDAQ:CRON), but here is why it might not be the best bet right now.
Motley Fool5 days ago
3 Pot Stocks Wall Street Bought in the First Quarter
These very popular marijuana stocks were scooped up by top-tier money managers.
Motley Fool5 days ago
Aurora Cannabis, Cronos Group, and Tilray Earnings Results Are In: Here's What They Could Mean for Canopy Growth
Based on its peers' results, Canopy Growth could be in for a pretty good quarter.
The Motley Fool6 days ago
Paranoia in the Markets: 4 Hot Cannabis Stocks to Ponder
Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) heads up a list of top Canadian legal marijuana stocks to snap up at the moment.
Motley Fool7 days ago
How Did Tilray Stack Up to the Competition?
Here's a look at Tilray's recent performance compared with its largest competitors.
Barrons.com7 days ago
A Top U.S. Pension Loads Up on Alibaba, Cronos, and Zillow Stock, Sells PG&E
The Wisconsin Retirement System, one of only two fully funded state pensions, also slashed its holdings in PG&E, the struggling California utility, last quarter.
Motley Fool10 days ago
This Pot Stock Has Turned Into Wall Street's Pinata
Wall Street has handed out not one, two, or three... but seven price-target cuts to this marijuana stock since the month began.
Motley Fool11 days ago
Is Tilray Finally a Buy?
Is Tilray's strong first-quarter report a good reason to buy this flagging pot stock?
Motley Fool11 days ago
Could This Be Cronos Group's Most Logical Acquisition Target?
Instead of acquiring additional production, Cronos may choose to fortify the strongest aspect of its business.
Yahoo Finance12 days ago
The argument for marijuana decriminalization without legalization
The advocacy group Smart Approaches to Marijuana (SAM) is pushing for a middle road approach, aiming for decriminalization without risking any unintended consequences of full legalization.
Baystreet12 days ago
Stocks in play: Cronos Group Inc.
Announced that it has entered into a multi-year supply agreement with MediPharm Labs Corp., whereby ...
The Motley Fool12 days ago
Despite Soaring Revenues, Cronos Group Inc. (TSX:CRON) Is Best Avoided
Cronos Group Inc. (TSX:CRON) (NASDAQ:CRON) recently released disappointing financial results. Here is why the pot company isn't worth the trouble.
Motley Fool12 days ago
3 Ways Marijuana Stocks Are Tricking Investors
Though perfectly legal, these accounting tricks are masking the true operating results of many pot stocks.
GlobeNewswire12 days ago
Cronos Group and MediPharm Labs Enter $30 Million Multi-Year Private Label Cannabis Concentrate Supply Agreement with Potential to Increase to $60 Million
MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.
GlobeNewswire12 days ago
Cronos Group and MediPharm Labs Enter Cannabis Concentrate Supply Agreement
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.
Oilprice.com13 days ago
The Marijuana Industry’s Dirty Little Secret
Cannabis cultivation requires enormous amounts of energy, and water, and the companies that employ smart solutions are now pulling ahead in the highly competitive cannabis boom